Compared with placebo , pitavastatin 1 , 2 , and 4 mg significantly reduced LDL-C from baseline by 23.5 % , 30.1 % , and 39.3 % , respectively , and in the open-label study 20.5 % of the subjects reached the LDL-C goal < 110 mg/dL ( 2.8 mmol/L ) .